1745 related articles for article (PubMed ID: 12637609)
21. [Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients].
Zhou L; Wang AH; Wang L; You JH; Li JM; Shen ZX
Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):13-7. PubMed ID: 18512309
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Kantarjian H; O'Brien S; Cortes J; Shan J; Giles F; Garcia-Manero G; Verstovsek S; Faderl S; Rios MB; Talpaz M
Cancer; 2003 Oct; 98(7):1430-7. PubMed ID: 14508830
[TBL] [Abstract][Full Text] [Related]
23. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
[TBL] [Abstract][Full Text] [Related]
24. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Branford S; Rudzki Z; Harper A; Grigg A; Taylor K; Durrant S; Arthur C; Browett P; Schwarer AP; Ma D; Seymour JF; Bradstock K; Joske D; Lynch K; Gathmann I; Hughes TP
Leukemia; 2003 Dec; 17(12):2401-9. PubMed ID: 14523461
[TBL] [Abstract][Full Text] [Related]
25. [Imatinib therapy for patients with chronic myelogenous leukemia].
Usui N
Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
[TBL] [Abstract][Full Text] [Related]
26. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
[TBL] [Abstract][Full Text] [Related]
27. Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
Guilhot F; Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Najman A; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J;
Semin Hematol; 2003 Apr; 40(2 Suppl 2):92-7. PubMed ID: 12783382
[TBL] [Abstract][Full Text] [Related]
28. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
Cohen MH; Johnson JR; Pazdur R
Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
[TBL] [Abstract][Full Text] [Related]
29. High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group.
Thielen N; van der Holt B; Verhoef GE; Ammerlaan RA; Sonneveld P; Janssen JJ; Deenik W; Falkenburg JH; Kersten MJ; Sinnige HA; Schipperus M; Schattenberg A; van Marwijk Kooy R; Smit WM; Chu IW; Valk PJ; Ossenkoppele GJ; Cornelissen JJ
Ann Hematol; 2013 Aug; 92(8):1049-56. PubMed ID: 23572137
[TBL] [Abstract][Full Text] [Related]
30. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
[TBL] [Abstract][Full Text] [Related]
31. Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Prescrire Int; 2003 Apr; 12(64):49-52. PubMed ID: 12669727
[TBL] [Abstract][Full Text] [Related]
32. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
[TBL] [Abstract][Full Text] [Related]
33. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
[TBL] [Abstract][Full Text] [Related]
34. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
Molnár L; Nagy A; Dávid M; Szomor A; Méhes G; Kovács G; Losonczy H
Orv Hetil; 2004 Apr; 145(17):901-7. PubMed ID: 15170967
[TBL] [Abstract][Full Text] [Related]
35. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib.
Koh Y; Kim I; Yoon SS; Kim BK; Kim DY; Lee JH; Lee KH; Park E; Kim HJ; Sohn SK; Joo YD; Kim SJ; Chung J; Shin HJ; Kim SH; Kim CS; Song HS; Kim MK; Hyun MS; Ahn JS; Jung CW; Park S;
Ann Hematol; 2010 Jul; 89(7):725-31. PubMed ID: 20179930
[TBL] [Abstract][Full Text] [Related]
36. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
Fruehauf S; Topaly J; Buss EC; Fischer T; Ottmann OG; Emmerich B; Müller MC; Schuld P; Balleisen L; Hehlmann R; Ho AD; Hochhaus A
Cancer; 2007 Apr; 109(8):1543-9. PubMed ID: 17340589
[TBL] [Abstract][Full Text] [Related]
37. [The efficacy of imatinib mesylate for 124 patients with chronic myeloid leukemia in accelerated and blastic phase].
Jiang Q; Chen SS; Jiang B; Jiang H; Qiu JY; Liu YR; Zhang Y; Qin YQ; Lu Y; Huang XJ; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):721-6. PubMed ID: 18457260
[TBL] [Abstract][Full Text] [Related]
38. Sustained superior long-term outcomes and cytogenetic responses with imatinib mesylate in chronic phase chronic myeloid leukaemia: report from a developing country.
Aziz Z; Iqbal J; Bano K; Faisal M; Akram M
Jpn J Clin Oncol; 2010 Jun; 40(6):549-55. PubMed ID: 20189974
[TBL] [Abstract][Full Text] [Related]
39. Quality of life on imatinib.
Hahn EA; Glendenning GA
Semin Hematol; 2003 Apr; 40(2 Suppl 2):31-6. PubMed ID: 12783373
[TBL] [Abstract][Full Text] [Related]
40. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
